Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:
Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem" or, the "Company") announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Tandem also intends to grant to the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes.
Q4 2019 Tandem Diabetes Care Inc Earnings Call
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strong domestic and international results for the fourth quarter of 2019.
Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.
On CNBC's "Mad Money Lightning Round," Jim Cramer said that Tandem Diabetes Care Inc (NASDAQ: TNDM) is heavily shorted. He finds that wrong, because the company had a great quarter. His favorite stock in the space is DexCom, Inc. (NASDAQ: DXCM).The tankers are traders and they don't necessarily offer a lot of value, said Cramer. He would be careful with Scorpio Tankers Inc. (NYSE: STNG).Cramer is not a buyer of LPL Financial Holdings Inc (NASDAQ: LPLA). He is not recommending any financial stocks at the moment.Carvana Co (NYSE: CVNA) has a very interesting business model, but it has to start to make money, said Cramer.JPMorgan Chase & Co. (NYSE: JPM) is an out-of-favor stock now, but it will be back in favor after the pandemic ends, said Cramer.Instead of CoStar Group Inc (NASDAQ: CSGP), Cramer would buy Mastercard Inc (NYSE: MA).See more from Benzinga * Cramer Shares His Thoughts On Slack, Archer Daniels Midland And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.
One stock that fits that bill is Tandem Diabetes Care, which had its Relative Strength (RS) Rating upgraded from 79 to 82 Thursday. While Tandem Diabetes Care is not near an ideal buying range right now, see if it manages to form and break out from a proper base. Tandem Diabetes Care earns the No. 21 rank among its peers in the Medical-Products industry group.
TNDM earnings call for the period ending March 31, 2020.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2020. In addition, due to the unknown depth and duration of the COVID-19 pandemic, the Company provided sales guidance for the second quarter 2020 and has withdrawn its financial guidance for the year ending December 31, 2020.
Q1 2020 Tandem Diabetes Care Inc Earnings Call
Recent regulatory go-aheads for Tandem Diabetes' (TNDM) insulin pump systems anticipated to boost global pump shipments as well as expand its customer base.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2020 results after the financial markets close on Thursday, April 30, 2020. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2020 financial and operating results.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
These two diabetes companies have been beating the market all year long, but that’s not the only reason you should consider investing in them.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders ("Annual Meeting") will be held in a virtual-only format due to continued public health concerns relating to COVID-19 and to prioritize the health and well-being of meeting participants. There is no change to the previously announced date and time of the meeting, which will be held on May 27, 2020 at 3:00pm Pacific Daylight Time.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) today announced that it will be notifying its customers of an information security incident involving five Tandem employee email accounts.
Investors might consider the company's products to be essential, but the business could face temporary problems getting products into the hands of new customers.
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) ("Tandem" or, the "Company") announced today the pricing of $250.0 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Tandem also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of Notes. The sale of the Notes is expected to close on May 15, 2020, subject to customary closing conditions.